1. Olsson, AG, Rossner, S, Walldius, G, Carlson, LA, Lang, PD(1977). Effect of BM 15075 on lipoprotein concentrations in different types of hyperlipoproteinemia. Atherosclerosis, 27, 279
2. Oster, P, Schlierf, G, Lang, PD, Andreas, J, Muhlbeyer, W, Schellenberg, B, Vollmar, J (1980). Effect of bezafibrate and clofibrate on diurnal lipid and lipoprotein profiles in healthy volunteers and patients with hypertriglyceridemia. In: Greten, H, Lang, PD, Schettler, G (eds.) “Lipoproteins and Coronary Heart Disease”, p.145. (New York, Baden-Baden, Cologne: Gerhard Witzstrock Publ. House)
3. Fellin, R, Martini, S, Crepaldi, G, Senin, U, Mannarino, E, Avellone, G, Notarbartolo, A, Capurso, A, D’Agostino, C, Montaguti, U, Celin, D, Descovich, GC, Mantovani E (1981). Multicenter trial with bezafibrate in primary hyperlipidemias. Curr Therap Res, 29,657
4. Olsson, AG, Lang, PD, Vollmar, J (1985). Effect of bezafibrate during 4.5 years of treatment of hyperlipoproteinemia. Atherosclerosis 55, 195
5. Sommariva, D, Tirrito, M, Bonfiglioli, D, Pogliaghi, I, Branchi, A, Ottomano, C, Bellintani, L (1985). Changes in serum lipoprotein pattern following bezafibrate. Differential effects in type IIa and in type IIb hyperlipoproteinemic patients. Pharmacol Res Comm, 17, 1181